Trials / Terminated
TerminatedNCT06655064
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
Prospective Observational Multicenter Registry Study to Assess the Impact & Long-Term Outcomes of 68Ga-PSMA-11 PET/CT Imaging Evaluations for Patients With Prostate Cancer (Newly Diagnosed, Suspected Recurrence P or Are Candidates for Radioligand Therapy)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited · Industry
- Sex
- Male
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they receive for their prostate cancer. Subjects will not be administered any medical diagnostic testing or therapy that they would not have normally undergone outside of participation in the registry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | None- Observational | None- Observational |
Timeline
- Start date
- 2025-01-30
- Primary completion
- 2025-06-17
- Completion
- 2025-06-17
- First posted
- 2024-10-23
- Last updated
- 2025-07-14
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06655064. Inclusion in this directory is not an endorsement.